{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:59:43Z","timestamp":1769637583766,"version":"3.49.0"},"reference-count":38,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2008,4,8]],"date-time":"2008-04-08T00:00:00Z","timestamp":1207612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:p>\n                    <jats:bold>Objective.\u2014<\/jats:bold>\n                    To evaluate the efficacy, tolerability, and safety of 3 different doses of divalproex sodium extended\u2010release vs placebo in the prophylaxis of migraine headaches in adolescents.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Background.\u2014<\/jats:bold>\n                    Divalproex sodium has been approved for migraine prophylaxis in adults, and previous uncontrolled data suggest divalproex sodium may be effective in preventing migraine in children and adolescents with acceptable tolerability.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.\u2014<\/jats:bold>\n                    This was a 12\u2010week, phase 3, randomized, placebo\u2010controlled, double\u2010blind, parallel\u2010group, multicenter study in approximately 300 adolescents aged 12 to 17\u2003years with migraine headaches. At the end of the baseline phase, subjects still meeting study criteria were randomized in a 1\u2003:\u20031\u2003:\u20031\u2003:\u20031 ratio to receive divalproex sodium extended\u2010release 250\u2003mg, 500\u2003mg, or 1000\u2003mg once daily, or placebo. The primary efficacy variable was reduction from baseline in 4\u2010week migraine headache rate for each active treatment group vs placebo. Standard safety assessments were conducted and testosterone and sex hormone\u2010binding globulin levels were collected for postmenarchal females.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.\u2014<\/jats:bold>\n                    There was no statistically significant treatment difference between any divalproex sodium extended\u2010release dose group and placebo for the primary efficacy variable, reduction from baseline in 4\u2010week migraine headache rate. There were no statistically significant differences in adverse events between any active treatment group and placebo. A notable dose\u2010related decrease in platelets was observed, and individuals in all 4 treatment groups had increases in ammonia levels; treatment differences in other laboratory variables were generally small. Among postmenarchal female subjects who were not taking hormonal contraceptives or other steroids, there was no statistically significant change in testosterone levels, but a statistically significant dose\u2010related increase in sex hormone\u2010binding globulin was observed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.\u2014<\/jats:bold>\n                    In the current study, divalproex sodium extended\u2010release did not differentiate from placebo in the prophylactic treatment of migraine headaches but was generally well\u2010tolerated in adolescents aged 12 to 17\u2003years.\n                  <\/jats:p>","DOI":"10.1111\/j.1526-4610.2008.01081.x","type":"journal-article","created":{"date-parts":[[2008,4,8]],"date-time":"2008-04-08T12:32:46Z","timestamp":1207657966000},"page":"1012-1025","source":"Crossref","is-referenced-by-count":50,"title":["Divalproex Extended\u2010Release in Adolescent Migraine Prophylaxis: Results of a Randomized, Double\u2010Blind, Placebo\u2010Controlled Study"],"prefix":"10.1111","volume":"48","author":[{"given":"George","family":"Apostol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger K.","family":"Cady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve A.","family":"Laforet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weining Z.","family":"Robieson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid M.","family":"Abi\u2010Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Saltarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,9]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/08830738060210092201"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.01094.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002761"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-2742"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K049"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000147332.41993.90"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1702103.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1995.00540270077022"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.11.1652"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2005.05.004"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.040008672.x"},{"key":"e_1_2_8_14_2","first-page":"32","article-title":"Low dose of sodium divalproate for the treatment of migraine","volume":"5","author":"Fragoso YD.","year":"2003","journal-title":"Med Gen Med"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.42404.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307380101601005"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02186.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1998.1801052.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2003.12.006"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.66.66_suppl_3.S23"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000125745.60149.c6"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00117.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.11.2034"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00610.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00528.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05050.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00817.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(99)00060-0"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307389400900318"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0887-8994(96)00052-5"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.17.1325.34418"},{"key":"e_1_2_8_32_2","unstructured":"Abbott Laboratories.Depakote ER (divalproex sodium extended\u2010release tablets) prescribing information. North Chicago IL 60064 USA. October 2006."},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307389701200709"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1021918104127"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.50.3.275"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2007.01.024"},{"key":"e_1_2_8_37_2","volume-title":"Tietz Clinical Guide to Laboratory Tests","author":"Wu A.","year":"2006"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.10.017"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.440"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1526-4610.2008.01081.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2008.01081.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:29:07Z","timestamp":1762090147000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/j.1526-4610.2008.01081.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1111\/j.1526-4610.2008.01081.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01081.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}